Key statistics
On Thursday, Enlivex Therapeutics Ltd (ENLV:NAQ) closed at 1.58, 37.39% above the 52 week low of 1.15 set on Aug 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.49 |
---|---|
High | 1.60 |
Low | 1.47 |
Bid | 1.53 |
Offer | 1.61 |
Previous close | 1.46 |
Average volume | 199.61k |
---|---|
Shares outstanding | 21.41m |
Free float | 18.76m |
P/E (TTM) | -- |
Market cap | 31.25m USD |
EPS (TTM) | -1.19 USD |
Data delayed at least 15 minutes, as of Sep 26 2024 20:58 BST.
More ▼
- Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
- Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
- Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
- Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
- Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
- Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
- Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
- Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
- Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
More ▼